Skip to main content

Advertisement

SpringerLink
Log in

STI571: A gene product-targeted therapy for leukemia

  • Published:
Current Oncology Reports Aims and scope Submit manuscript

Abstract

Chronic myelogenous leukemia (CML) is a clonal hematopoietic stem-cell disorder characterized by the (9:22) translocation and resultant production of the constitutively activated bcr-abl tyrosine kinase. Characterized clinically by marked myeloid proliferation, it invariably terminates in an acute leukemia. Conventional therapeutic options include interferon-based regimens and stem-cell transplantation, with stem-cell transplantation being the only curative therapy. Through rational drug development, STI571, a bcr-abl tyrosine kinase inhibitor, has emerged as a paradigm for gene product-targeted therapy, offering new hope for expanded treatment options for patients with CML.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Nowell PC, Hungerford DA: A minute chromosome in human chronic granulocytic leukemia. Science 1960, 132:1497–1501.

    Google Scholar 

  2. Rowley JD: A new consistent chromosomal abnormality in chronic myelogenous leukemia identified by quinacrine fluorescence and Giemsa staining. Nature 1973, 243:290–293.

    Article  PubMed  CAS  Google Scholar 

  3. de Klein A, van Kessel AG, Grosveld G, et al.: A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia. Nature 1982, 300:765–767.

    Article  PubMed  Google Scholar 

  4. Heisterkamp N, Stephenson JR, Groffen J, et al.: Localization of the c-ab1 oncogene adjacent to a translocation break point in chronic myelocytic leukaemia. Nature 1983, 306:239–242.

    Article  PubMed  CAS  Google Scholar 

  5. Shtivelman E, Lifshitz B, Gale RP, Canaani E: Fused transcript of abl and bcr genes in chronic myelogenous leukaemia. Nature 1985, 315:550–554.

    Article  PubMed  CAS  Google Scholar 

  6. Heisterkamp N, Stam K, Groffen J, et al.: Structural organization of the bcr gene and its role in the Ph’ translocation. Nature 1985, 315:758–761.

    Article  PubMed  CAS  Google Scholar 

  7. Abelson HT, Rabstein LS: Lymphosarcoma: virus-induced thymic-independent disease in mice. Cancer Res 1970, 30:2213–2222.

    PubMed  CAS  Google Scholar 

  8. Witte ON, Dasgupta A, Baltimore D: Abelson murine leukaemia virus protein is phosphorylated in vitro to form phosphotyrosine. Nature 1980, 283:826–831.

    Article  PubMed  CAS  Google Scholar 

  9. Witte ON, Goff S, Rosenberg N, Baltimore D: A transformationdefective mutant of Abelson murine leukemia virus lacks protein kinase activity. Proc Natl Acad Sci U S A 1980, 77:4993–4997.

    Article  PubMed  CAS  Google Scholar 

  10. Lugo TG, Pendergast AM, Muller AJ, Witte ON: Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science 1990, 247:1079–1082.

    Article  PubMed  CAS  Google Scholar 

  11. McLaughlin J, Chianese E, Witte ON: In vitro transformation of immature hematopoietic cells by the P210 BCR/ABL oncogene product of the Philadelphia chromosome. Proc Natl Acad Sci U S A 1987, 84:6558–6562.

    Article  PubMed  CAS  Google Scholar 

  12. Gishizky ML, Witte ON: Initiation of deregulated growth of multipotent progenitor cells by bcr-abl in vitro. Science 1992, 256:836–839.

    Article  PubMed  CAS  Google Scholar 

  13. Daley GQ, Van Etten RA, Baltimore D: Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science 1990, 247:824–830.

    Article  PubMed  CAS  Google Scholar 

  14. Heisterkamp N, Jenster G, ten Hoeve J, et al.: Acute leukaemia in bcr/abl transgenic mice. Nature 1990, 344:251–253.

    Article  PubMed  CAS  Google Scholar 

  15. Neshat MS, Raitano AB, Wang HG, et al.: The survival function of the Bcr-Abl oncogene is mediated by Bad-dependent and -independent pathways: roles for phosphatidylinositol 3-kinase and Raf. Mol Cell Biol 2000, 20:1179–1186.

    Article  PubMed  CAS  Google Scholar 

  16. Horita M, Andreu EJ, Benito A, et al.: Blockade of the Bcr-Abl kinase activity induces apoptosis of chronic myelogenous leukemia cells by suppressing signal transducer and activator of transcription 5-dependent expression of Bcl-xL. J Exp Med 2000, 191:977–984.

    Article  PubMed  CAS  Google Scholar 

  17. Bazzoni G, Carlesso N, Griffin JD, Hemler ME: Bcr/Abl expression stimulates integrin function in hematopoietic cell lines. J Clin Invest 1996, 98:521–528.

    PubMed  CAS  Google Scholar 

  18. Senechal K, Heaney C, Druker B, Sawyers CL: Structural requirements for function of the Crkl adapter protein in fibroblasts and hematopoietic cells. Mol Cell Biol 1998, 18:5082–5090.

    PubMed  CAS  Google Scholar 

  19. Yaish P, Gazit A, Gilon C, Levitzki A: Blocking of EGF-dependent cell proliferation by EGF receptor kinase inhibitors. Science 1988, 242:933–935.

    Article  PubMed  CAS  Google Scholar 

  20. Kaur G, Gazit A, Levitzki A, et al.: Tyrphostin induced growth inhibition: correlation with effect on p210bcr-abl autokinase activity in K562 chronic myelogenous leukemia. Anticancer Drugs 1994, 5:213–222.

    Article  PubMed  CAS  Google Scholar 

  21. Anafi M, Gazit A, Zehavi A, et al.: Tyrphostin-induced inhibition of p210bcr-abl tyrosine kinase activity induces K562 to differentiate. Blood 1993, 82:3524–3529.

    PubMed  CAS  Google Scholar 

  22. Druker BJ, Tamara S, Buchdunger E, et al.: Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996, 2:561–566.

    Article  PubMed  CAS  Google Scholar 

  23. Deininger MW, Goldman JM, Lydon N, Melo JV: The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells. Blood 1997, 90:3691–3698.

    PubMed  CAS  Google Scholar 

  24. Marley SB, Deininger MW, Davidson RJ, et al.: The tyrosine kinase inhibitor STI571, like interferon-alpha, preferentially reduces the capacity for amplification of granulocytemacrophage progenitors from patients with chronic myeloid leukemia. Exp Hematol 2000, 28:551–557.

    Article  PubMed  CAS  Google Scholar 

  25. Kasper B, Fruehauf S, Schiedlmeier B, et al.: Favorable therapeutic index of a p210(BCR-ABL)-specific tyrosine kinase inhibitor: activity on lineage-committed and primitive chronic myelogenous leukemia progenitors. Cancer Chemother Pharmacol 1999, 44:433–438.

    Article  PubMed  CAS  Google Scholar 

  26. Gambacorti-Passerini C, le Coutre P, Mologni L, et al.: Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL+ leukemic cells and induces apoptosis. Blood Cells Mol Dis 1997, 23:380–394.

    Article  PubMed  CAS  Google Scholar 

  27. Carroll M, Ohno-Jones S, Tamura S, et al.: CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins. Blood 1997, 90:4947–4952.

    PubMed  CAS  Google Scholar 

  28. Beran M, Cao X, Estrov Z, et al.: Selective inhibition of cell proliferation and BCR-ABL phosphorylation in acute lymphoblastic leukemia cells expressing Mr 190,000 BCR-ABL protein by a tyrosine kinase inhibitor (CGP-57148). Clin Cancer Res 1998, 4:1661–1672.

    PubMed  CAS  Google Scholar 

  29. le Coutre P, Mologni L, Cleris L, et al.: In vivo eradication of human BCR/ABL-positive leukemia cells with an ABL kinase inhibitor. J Natl Cancer Inst 1999, 91:163–168.

    Article  PubMed  Google Scholar 

  30. Druker BJ, Talpaz M, Resta D, et al.: Clinical efficacy and safety of a Abl specific tyrosine kinase inhibitor as targeted therapy for chronic myelogenous leukemia [abstract]. Blood 1999, 94:368a. The results of the first clinical trials with STI571 in chronic-phase CML patients who had failed interferon therapy.

    Google Scholar 

  31. Talpaz M, Sawyers CL, Kantarjain H, et al.: Activity of an ABL specific tyrosine kinase inhibitor in patients with Bcr-Abl positive acute leukemias, including chronic myelogenous leukemia in blast crisis [abstract]. Proc ASCO 2000, 18:4a. An update on the results with STI571 in patients with CML in blast crisis and Ph-positive ALL.

    Google Scholar 

  32. le Coutre P, Tassi E, Varella-Garcia M, et al.: Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification. Blood 2000, 95:1758–1766.

    PubMed  Google Scholar 

  33. Mahon FX, Deininger MW, Schultheis B, et al.: Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. Blood 2000, 96:1070–1079.

    PubMed  CAS  Google Scholar 

  34. Gambacorti-Passerini C, Barni R, le Coutre P, et al.: Role of alpha1 acid glycoprotein in the in vivo resistance of human BCR-ABL(+) leukemic cells to the Abl inhibitor STI571. J Natl Cancer Inst 2000, 92:1641–1650.

    Article  PubMed  CAS  Google Scholar 

  35. Druker BJ, Lydon NB: Lessons learned from the development of an Abl kinase inhibitor for chronic myelogenous leukemia. J Clin Invest 2000, 105:3–7. A review of the development of STI571 from bench to bedside.

    Article  PubMed  CAS  Google Scholar 

  36. Thiesing JT, Ohno-Jones S, Kolibaba KS, Druker BJ: Efficacy of STI571, an Abl tyrosine kinase inhibitor, in conjunction with other anti-leukemic agents against Bcr-Abl-positive cells. Blood 2000, 96:3195–3199. See annotation for reference [37].

    PubMed  CAS  Google Scholar 

  37. Fang G, Kim CN, Perkins CL, et al.: CGP57148B (STI-571) induces differentiation and apoptosis and sensitizes Bcr-Abl positive human leukemia cells to apoptosis due to antileukemic drugs. Blood 2000, 96:2246–2253. These two articles provide the preclinical rationale for combination studies of STI571 with a variety of antileukemic agents, including interferon, Ara-C, and daunorubicin.

    PubMed  CAS  Google Scholar 

  38. Melo JV: The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype. Blood 1996, 88:2375–2384.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Leukemia Program, Division of Hematology and Medical Oncology, Department of Medicine, Oregon Health Sciences University, OP28, 3181 SW Sam Jackson Park Road, 97201, Portland, OR, USA

    Michael J. Mauro MD & Brian J. Druker MD

Authors
  1. Michael J. Mauro MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Brian J. Druker MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mauro, M.J., Druker, B.J. STI571: A gene product-targeted therapy for leukemia. Curr Oncol Rep 3, 223–227 (2001). https://doi.org/10.1007/s11912-001-0054-z

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11912-001-0054-z

Keywords

Search

Navigation